Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
With
Millennium Pharmaceuticals, Inc.
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with relapsed or refractory Hodgkin lymphoma who have previously received autologous stem cell transplant.
Histologically confirmed CD30-positive disease; tissue from the most recent post diagnostic biopsy of relapsed/refractory disease must be available for confirmation of CD30 expression via slides or tumor block.
Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease of at least 1.5 cm as documented by spiral computed tomography.
At US sites patients greater than or equal to 12 years of age may be enrolled. At non-US sites patients must be greater than or equal to 18 years of age.
You may not be if
Previous treatment with brentuximab vedotin.
Previously received an allogeneic transplant.
Congestive heart failure, Class III or IV, by the New York Heart Association criteria.
History of another primary malignancy that has not been in remission for at least 3 years.
Known cerebral/meningeal disease.
Clareo Health | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
